Findings

What do systematic reviews say?

61 questions · 70 findings · 27 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 7 · 10%GRADE not reported 1 · 1.4%Very low 13 · 18.6%Low 26 · 37.1%Moderate 19 · 27.1%High 4 · 5.7%

Oral plus intravenous acetylcysteine vs intravenous acetylcysteine

All‐cause mortality · people with paracetamol (acetaminophen) overdose

1 finding from 1 review

Interventions for paracetamol (acetaminophen) overdose 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Very low

Standard intravenous acetylcysteine regimen (20.5 hour) vs shorter intravenous acetylcysteine regimen (12 hour)

All‐cause mortality · people with paracetamol (acetaminophen) overdose

1 finding from 1 review

Interventions for paracetamol (acetaminophen) overdose 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 222 participants
Very low

Intravenous acetylcysteine vs placebo

All‐cause mortality · people with fulminant hepatic failure secondary to paracetamol (acetaminophen) overdose

Intravenous acetylcysteine may leads to lower mortality compared with placebo (low certainty).

1 finding from 1 review

Interventions for paracetamol (acetaminophen) overdose 2018 · Cochrane Headline outcomes only
Peto OR 0.29 [0.09, 0.94]
1 study · 50 participants
Low

IVIg vs placebo

All‐cause mortality · NSTI

Intravenous immunoglobulin showed no clear difference in mortality compared with placebo (low certainty).

1 finding from 1 review

Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
RR 1.17 [0.42, 3.23]
1 study · 100 participants
Low

Erythropoietin (regardless of rout) with intravenous iron vs IV iron

Maternal death · women with postpartum iron deficiency anaemia

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for women with postpartum iron deficiency anaemia 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intravenous iron vs oral iron

Maternal mortality Clinical assessment · women with postpartum iron deficiency anaemia

Intravenous iron showed no clear difference in maternal mortality Clinical assessment compared with oral iron (low certainty).

1 finding from 1 review

Treatment for women with postpartum iron deficiency anaemia 2015 · Cochrane Headline outcomes only
RR 2.95 [0.12, 71.96]
2 studies · 374 participants
Low

Subcutaneous EPO with intravenous iron and oral iron vs intravenous iron with oral iron (Comparison 12)

Maternal mortality ‐ not reported · women with postpartum iron deficiency anaemia

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for women with postpartum iron deficiency anaemia 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Subcutaneous EPO 10,000 U of doses with intravenous iron vs IV iron

Maternal mortality ‐ not reported · women with postpartum iron deficiency anaemia

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for women with postpartum iron deficiency anaemia 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Ultrasound‐assisted catheter‐directed thrombolysis plus standard intravenous heparinisation vs standard intravenous heparinisation

All‐cause mortality(7‐day) · people with intermediate‐risk (submassive) APE

1 finding from 1 review

Catheter‐directed therapies for the treatment of high risk (massive) and intermediate risk (submassive) acute… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 59 participants
GRADE not reported

Initial infusion rate of intravenous acetylcysteine over 15 minutes vs 60 minutes

All‐cause mortality · people with paracetamol (acetaminophen) overdose

1 finding from 1 review

Interventions for paracetamol (acetaminophen) overdose 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 180 participants
Very low

IVIg vs acetylsalicylic acid (ASA)

Mortality (all‐cause) · people undergoing initial treatment for KD

1 finding from 1 review

Intravenous immunoglobulin for the treatment of Kawasaki disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Ultrasound‐assisted catheter‐directed thrombolysis plus standard intravenous heparinisation vs standard intravenous heparinisation

All‐cause mortality (90‐day) · people with intermediate‐risk (submassive) APE

It is very uncertain whether ultrasound‐assisted catheter‐directed thrombolysis plus standard… changes all‐cause mortality (90‐day) compared with standard intravenous heparinisation (very low certainty).

1 finding from 1 review

Catheter‐directed therapies for the treatment of high risk (massive) and intermediate risk (submassive) acute… 2022 · Cochrane Headline outcomes only
OR 0.31 [0.01, 7.96]
1 study · 59 participants
Very low

Summary of findings table ‐ Continuous infusion of intravenous loop diuretics vs bolus injection of intravenous loop diuretics

Cardiovascular mortality ‐ not measured · adults (aged greater than 18 years) with acute heart failure

The review found no eligible studies for this question.

1 finding from 1 review

Continuous infusion versus bolus injection of loop diuretics for acute heart failure 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Continuous infusion of intravenous loop diuretics vs bolus injection of intravenous loop diuretics

Mortality before hospital discharge · adults (aged greater than 18 years) with acute heart failure

Summary of findings table ‐ Continuous infusion of intravenous loop… showed no clear difference in all‐cause mortality (from admission to discharge) compared with bolus injection of intravenous loop diuretics (low certainty).

1 finding from 1 review

Continuous infusion versus bolus injection of loop diuretics for acute heart failure 2024 · Cochrane Headline outcomes only
RR 1.53 [0.81, 2.9]
5 studies · 530 participants
Low

Intravenous iron with oral iron vs oral iron

Maternal death · women with postpartum iron deficiency anaemia

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for women with postpartum iron deficiency anaemia 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

IVIg vs placebo or no intervention

28‐Day all cause mortality (adult studies) · adult patients with sepsis, severe sepsis and septic shock

Polyclonal intravenous immunoglobulin (IVIG) probably leads to lower all‐cause mortality, adults, standard polyclonal IVIG compared with placebo or no intervention (moderate certainty).

5 findings from 1 review

Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock 2013 · Cochrane Headline outcomes only
RR 0.81 [0.7, 0.93]
10 studies · 1430 participants
Moderate
Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock 2013 · Cochrane Headline outcomes only
RR 0.66 [0.51, 0.85]
7 studies · 528 participants
Moderate
Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock 2013 · Cochrane Headline outcomes only
RR 0.97 [0.81, 1.15]
5 studies · 945 participants
High

Show 2 more findings

Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock 2013 · Cochrane Headline outcomes only
RR 1.02 [0.84, 1.24]
3 studies · 683 participants
High
Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock 2013 · Cochrane Headline outcomes only
RR 0.82 [0.56, 1.19]
2 studies · 262 participants
Moderate

IVIg vs placebo or no intervention

All‐cause mortality, neonates, standard polyclonal IVIG · neonates with sepsis, severe sepsis and septic shock

Polyclonal intravenous immunoglobulin (IVIG) showed no clear difference in all‐cause mortality, neonates, standard polyclonal IVIG compared with placebo or no intervention (moderate certainty).

2 findings from 1 review

Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock 2013 · Cochrane Headline outcomes only
RR 1 [0.92, 1.08]
5 studies · 3667 participants
Moderate
Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock 2013 · Cochrane Headline outcomes only
RR 1.01 [0.93, 1.09]
3 studies · 3561 participants
High

IVIg vs placebo or no intervention

All‐cause mortality, neonates, IgM‐enriched polyclonal IVIG · neonates with sepsis, severe sepsis and septic shock

Polyclonal intravenous immunoglobulin (IVIG) showed no clear difference in all‐cause mortality, neonates, IgM‐enriched polyclonal IVIG compared with placebo or no intervention (low certainty).

1 finding from 1 review

Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock 2013 · Cochrane Headline outcomes only
RR 0.57 [0.31, 1.04]
3 studies · 164 participants
Low

IVIg vs different infusion regimens of IVIG

Mortality (all‐cause) (up to 7 weeks) · people undergoing initial treatment for KD

1 finding from 1 review

Intravenous immunoglobulin for the treatment of Kawasaki disease 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 549 participants
Moderate

IVIg vs prednisolone

Mortality (all‐cause) (up to 30 days) · people undergoing initial treatment for KD

1 finding from 1 review

Intravenous immunoglobulin for the treatment of Kawasaki disease 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 90 participants
Low